NEWTOWN, Pa. , May 03, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), announced that the Company will present
Underwriter’s Option to Purchase Additional Securities Exercised in Full NEWTOWN, Pa. , May 01, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to
NEWTOWN, Pa. , April 27, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS),
Onconova receives productive pre-IND guidance from FDA regarding first-in-class compound ON 123300 Preclinical data reveals differential metabolism of ON 123300 in male versus female rodents, with implications for development of dosing strategy Development program is in collaboration with HanX
First presentation from dose exploration cohorts in an expanded trial addressing urinary safety of the novel combination therapy in higher risk patients with Myelodysplastic Syndromes (MDS) Study demonstrates elimination of grade 3 or grade 4 urinary adverse events after implementation of
NEWTOWN, Pa. , March 15, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), will present new data on ON 123300, a
NEWTOWN, Pa. , March 08, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided
NEWTOWN, Pa. , March 06, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), will present at
• Pint Pharma to Make Upfront Investment in Onconova • Onconova also Eligible to Receive up to $42.75 Million in Regulatory and Sales Milestones NEWTOWN, Pa. , March 05, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on
Effect of rigosertib plus azacitidine treatment on epigenetic modulation in cancer cell-lines and patient derived bone marrow cells Study suggests potential novel clinical strategies to improve outcomes for patients with higher-risk Myelodysplastic Syndromes and reversal of resistance to treatment
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Thursday, March 8, 2018 NEWTOWN, Pa. , March 01, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat
Exploration of dose and schedule of administration in an expanded Phase 2 trial with the objective of designing a pivotal Phase 3 trial Risk-mitigation strategies to reduce the incidence of urinary tract adverse events NEWTOWN, Pa. , March 01, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc.
Product stability studies for rigosertib, a Phase 3 clinical stage product in development for Myelodysplastic Syndromes (MDS) Discovery of a novel kinase inhibitor, ON 150030, a Type 1 inhibitor of FLT3 and Src for relapsed and refractory Acute Myeloid Leukemia (AML) NEWTOWN, Pa. , Feb.
NEWTOWN, Pa. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS),
NEWTOWN, Pa. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS),